Skip to main content
OpenTrials
Completed

NCT Number: NCT02053025

Appetite Regulation and Mycoprotein

The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Appetite Body Weight Energy Intake Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Imperial College NIHR CRF

London, W12 0NN, United Kingdom

About this study

Owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing T2DM

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females between the ages of 18 and 65
  • body mass index (BMI) 25-32kg/m2
  • Weight stable over the past 6 months
  • No known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels.
  • No paracetamol or other analgesic in the previous 48 hours
  • A score of <2.5 in the Dutch Eating Behaviour Questionnaire (DEBQ)
  • A score of <2 in the SCOFF questionnaire

Exclusion criteria

  • Persons outside the age and BMI ranges stated above
  • Pregnant and lactating women
  • Weight variation of greater than 5% in the last 6 months
  • Any diagnosed major illness
  • Any paracetamol or analgesic intake in the last 48 hours
  • Diagnosed eating disorder
  • Allergy to mycoprotein or mushrooms
  • Regular consumption of Quorn products
  • Dislike of any of the test foods or drinks
  • A score of >2.5 in the Dutch Eating Behaviour questionnaire
  • A score of 2 or more in the SCOFF questionaire

Treatment and study plan

mycoprotein

Dietary Supplement

Control protein

Dietary Supplement

Primary outcomes

  1. Energy intake at ad-libitum meal

    Time frame: upon completion of all participants, expected timeframe: 2 years

    Energy intake will be assessed during an ad-libitum meal at 180 minutes at the end of each study visit. Participants will be offered a meal in excess and asked to eat until they feel comfortably full. The meal will be weighed before and after consumption and energy intake will be calculated from the manufacturer's reported nutritional composition.

Secondary outcomes

  1. Glucagon-like peptide-1 (GLP-1)

    Time frame: upon completion of all participants, expected at 2 years

    Plasma glucagon-like peptide-1 (GLP-1) concentrations will be measured by radioimmunoassay (RIA) at the end of the study

  2. peptide tyrosine-tyrosine (PYY) levels

    Time frame: upon completion of all participants, expected at 2 years

    Plasma peptide tyrosine-tyrosine (PYY) concentrations will be measured by radioimmunoassay (RIA) at the end of the study

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Registry information

Acronym: mycoprotein

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Feb 3, 2014
Registry last updated
Oct 16, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.